Volume 1.04 | Feb 5

Prostate Cell News 1.04, February 5, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Evaluation of the Frequency of Putative Prostate Cancer Stem Cells in Primary and Metastatic Prostate Cancer
In established metastases no single or combination of marker expression profiles identify the established metastatic phenotype, although CD44 expression was shown to be more frequent in metastases that in primary cancers. [Prostate]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


Loss of Gene Function Makes Some Prostate Cancer Cells More Aggressive, Researchers Find
The study in mice found that eliminating the DAB2IP scaffolding in human carcinoma cells caused them to change from epithelial cells to mesenchymal cells – a hallmark of metastatic cancer. [Press release from UT Southwestern Medical Center discussing online prepublication in Proceedings of the National Academy of Sciences]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies



Estrogen Receptor-Beta Activated Apoptosis in Benign Hyperplasia and Cancer of the Prostate is Androgen Independent and TNF(Alpha) Mediated
Data are indicative of the therapeutic potential of estrogen receptor-beta agonist for treatment of prostate cancer and/or benign prostatic hyperplasia with or without androgen withdrawal. [Proc Natl Acad Sci]

Role of Cationic Channel Transient Receptor Potential Vanilloid 2 (TRPV2) in Promoting Prostate Cancer Migration and Progression to Androgen Resistance
Researchers report that the nonselective cationic channel transient receptor potential vanilloid 2 is a distinctive feature of castration-resistant prostate cancer. [Cancer Res]

Variability in the Androgen Response of Prostate Epithelium to 5(Alpha)-Reductase Inhibition: Implications for Prostate Cancer Chemoprevention
Findings suggest that androgen receptor levels may predict the chemopreventive efficacy of 5(alpha)-reductase inhibitors. [Cancer Res]

Flavokawain B, a Kava Chalcone, Exhibits Robust Apoptotic Mechanisms on Androgen Receptor-Negative, Hormone-Refractory Prostate Cancer Cell Lines and Reduces Tumor Growth in a Preclinical Model
Resarchers have shown that flavokawain B, a kava chalcone, is about 4 to 12 fold more effective in reducing the cell viabilities of androgen receptor (AR)-negative, hormone-refractory prostate cancer cell lines DU145 and PC-3 than AR-positive, hormone-sensitive prostate cancer cell lines LAPC4 and LNCaP, with minimal effect on normal prostatic epithelial and stromal cells. [Int J Cancer]

Gossypol Induces Apoptosis by Activating p53 in Prostate Cancer Cells and Prostate Tumor-Initiating Cells
These studies show for the first time that gossypol treatment induces DNA damage and activates p53. [Mol Cancer Ther]

CCR9-Mediates PI3K/AKT Dependent Anti-Apoptotic Signals in Prostate Cancer Cells and Inhibition of CCR9-CCL25 Interaction Enhances the Cytotoxic Effects of Etoposide
Researchers show that CC chemokine receptor 9 and its natural ligand CCL25 interaction up regulates anti-apoptotic proteins and down regulate activation of caspase-3 in prostate cancer cells. [Int J Cancer]

Inhibition of Glycogen Synthase Kinase-3(Beta) Promotes Nuclear Export of the Androgen Receptor through a CRM1-Dependent Mechanism in Prostate Cancer Cell Lines

Results suggest that glycogen synthase kinase-3(beta) is an important element not only in androgen receptor (AR) stability but also significantly alters nuclear translocation of the AR, thereby modulating the androgenic response of human prostate cancer cells. [J Cell Biochem]


Finasteride to Prevent Prostate Cancer: Should All Men or Only a High-Risk Subgroup Be Treated?
Researchers sought to determine whether prostate-specific antigen levels could identify a high-risk subgroup for which the benefits of finasteride treatment outweigh the potential harms. [J Clin Oncol]

Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-Century Radiotherapy
Investigators evaluated preoperative prognostic risk factors to predict organ-confined, locally recurrent prostate cancer after primary radiotherapy. [Eur Urol]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies


Launch of Ipsen’s Decapeptyl® 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer
Ipsen and Debiopharm Group announce the launch by Ipsen in France of Decapeptyl® LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. [Business Wire]

Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer
Progenics Pharmaceuticals, Inc. announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells. [Progenics Pharmaceuticals Press Release]


Notice of Availability of Administrative Supplements for R25 Science Education Grants (NOT-DA-10-007) [National Institutes of Health, United States]

Recovery Act Limited Competition: Program to Enhance National Institutes of Health-Supported Global Health Research Involving Human Subjects (S07) (RFA-OD-10-006) [National Institutes of Health, United States]

Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-001)
[National Institutes of Health, United States]

Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) (PAR-10-096) [National Heart, Lung, and Blood Institute, United States]

NIDDK Centers of Excellence in Molecular Hematology (P30) (RFA-DK-09-013) [National Institute of Diabetes and Digestive and Kidney Diseases, United States]

Public Consultation (MLX 366): Intention to Amend the Medicines for Human Use (Prescribing by EEA Practitioners) Regulations 2008 (SI 2008/1692) [The Medicines and Healthcare Products Regulatory Agency, United Kingdom]


SMi’s Second Annual Stem Cells 2010
February 15-16, 2010
London, United Kingdom

Keystone Symposia: Stem Cell Differentiation and Dedifferentiation (B4)
February 15-20, 2010
Keystone, United States

5th Annual Stem Cell Summit
February 16, 2010
New York, United States

Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer
February 24-27, 2010
Washington, DC, United States

The 3rd World Congress on Controversies in Urology (CURy)
February 25-28, 2010
Athens, Greece

2010 Genitourinary Cancers Symposium: Progress in Multidisciplinary Management
March 5-7, 2010
San Francisco, United States

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

American Urological Association (AUA) Annual Meeting
May 29-June 2, 2010
San Francisco, United States

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

2010 World Cancer Congress 
August 18-21, 2010
Shenzhen, China


Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us